The study and its comparison
A 1987 trial reported fewer recurrences, less severe symptoms and faster healing with 3 grams daily of lysine over six months; 52 participants completed it. A 1984 trial in 21 patients found no substantial benefit with 1.2 grams daily. [1][2]
The different regimens and study populations prevent a clean dose comparison. A positive higher-dose trial and negative lower-dose trial do not prove that increasing the dose explains the difference. [1][2]
What the finding establishes
These small older studies are not a complete modern evidence review. Neither directly tested zinc combinations or an amino-acid restriction diet. Funding and conflicts were not established from the retrieved abstracts. They do not justify replacing established treatment or interpreting an absence of reported problems as unlimited-dose safety. [1][2]
A hypothetical distinction
Imagine two separate trials differ in both dose and participants. Their results cannot isolate which difference caused the disagreement.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Success of L-lysine therapy in frequently recurrent herpes simplex infection. Treatment and prophylaxis.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product. - Failure of lysine in frequently recurrent herpes simplex infection. Treatment and prophylaxis.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.